bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract C074: Somatic mutations in the PIK3CA gene and its prognostic implications among Ethiopian breast cancer patients
Authors: Woldesonbet Zelalem Desalegn , Yohannes Meron , Addissie Adamu , Abebe Tamrat , Kantelhardt Eva Johanna , Vetter Martina 
Published: December 2023

Abstract
Purpose: The phosphatidylinositol-4, 5-bisphosphate 3-kinase (PIK3CA), catalytic subunit alpha (c) is frequently mutated in breast cancer (BC). Although the biological impact of PIK3CA mutations in BC has been studied in various parts of the world, limited data is available from sub-Saharan Africa. In this study, the frequency and the prognostic role of PIK3CA mutations were investigated among BC patients from Ethiopia. Methods: Formalin-fixed paraffin-embedded blocks and fresh frozen BC tissue samples were collected from patients newly diagnosed with BC. Histopathological evaluation was carried out using immunohistochemistry (IHC). PIK3CA mutation profiling was carried out using TaqMan® Mutation detection assay. The association between PIK3CA mutation status and clinical and histopathological features was evaluated. A survival regression (Cox’s model) was employed to assess the effect of PIK3CA mutation and other variables on survival. Results: The prevalence of the PIK3CA mutations was 20.4%. Mutation of the PIK3CA gene was mainly observed among younger (24%), early pT stage (19.4%), and G1/G2 tumors (22.3%). The proportion of mutation was 24.4%, 27.3% and 20% in ER+, PR+ and HER2- tumors, respectively. A marked difference was observed in the PIK3CA mutation frequency across the four major tumor subgroups. However, most of the mutated tumors were found among HR+/HER2− (24.1%) followed by HR+/HER2+ tumors (27.8%). In his study, only TNBC was negatively associated with the proportion of mutation in the PIK3CA gene (p-value= 0.02) in comparison to HR+/HER2- tumors. In multivariate Cox’s regression analysis, the advanced pT stage and HR−/HER2- IHC group independently predicted worse overall survival. However, PIK3CA mutation status was not associated with survival. Conclusions: The PIK3CA mutation was relatively high in HR+ tumors. Such relatively higher molecular aberrations among HR+ tumors can provide a benefit in choosing the best therapeutic option for breast cancer.
Citation Format: Zelalem Desalegn Woldesonbet, Meron Yohannes, Adamu Addissie, Tamrat Abebe, Eva Johanna Kantelhardt, Martina Vetter. Somatic mutations in the PIK3CA gene and its prognostic implications among Ethiopian breast cancer patients [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr C074.
Abstract C077: Effects of treatment delays on colorectal cancer survival
Authors: Montero Percy Guzman 
Published: December 2023

Abstract
Introduction: Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide. Understanding the influence of patient characteristics and treatment modalities on delays in care and related outcomes is crucial for optimizing treatment strategies and improving patient survival. Methods: A retrospective analysis of 2,359 CRC patients from the PLCO trial was conducted to assess the relationships between treatment initiation delays and survival outcomes. Descriptive statistics, Spearman's correlation coefficients, and Cox proportional hazards regression analyses were employed to analyze the data. Results: Among other factors, patients with disabilities and those using ibuprofen exhibited a higher hazard ratio and a lower hazard ratio, respectively, indicating the influence of these factors on patient outcomes. Despite examining multiple waiting time predictors, no significant associations were found between these predictors and mortality risk. The model's non-significant likelihood ratio chi-square and log-likelihood value suggested that it did not provide an adequate fit to the data. Discussion: This study highlights the importance of understanding the relationships between patient characteristics, treatment modalities, and their impact on patient outcomes in CRC patients. While curative resection was significantly associated with improved survival, neoadjuvant chemotherapy did not demonstrate a significant effect on mortality. The lack of association between waiting time predictors and mortality risk suggests the need to explore additional factors influencing patient outcomes. Conclusion: In conclusion, the study provides valuable insights into the relationships between patient characteristics, treatment modalities, and their impact on patient outcomes in CRC patients. Further research is needed to identify additional factors that may influence mortality risk and to optimize treatment strategies for this patient population.
Citation Format: Percy Guzman Montero. Effects of treatment delays on colorectal cancer survival [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr C077.
Abstract C105: Addressing stomach cancer disparities in low-income New York City Chinese American immigrants: A randomized controlled trial
Authors: Kwon Simona , Tan Yi-Ling , Vang Suzanne , Mui Angel , Pan Janet , Chong Stella , Wyatt Laura , Zhao Qiuqu , Williams Renee , Xiao Patrick , Malieckal Anju , Gamagaris Zoi , Trinh-Shevrin Chau 
Published: December 2023

Abstract
Background Stomach cancer is the most common infection-related cancer worldwide. In the United States, Chinese Americans, especially recent immigrants, experience a disproportionate burden of stomach cancer incidence and mortality. Infection with the bacterium Helicobacter pylori (H. Pylori) is the strongest risk factor for stomach cancer. However, adherence to the complex H. pylori treatment regimen is challenging for Chinese New Yorkers with limited English proficiency (LEP) and low health literacy. By linking bilingual/bicultural community health workers (CHWs) to Chinese-speaking patients in clinical settings – the first intervention of its kind that targets this at-risk population – we aim to help participants facilitate H. pylori eradication and stomach cancer prevention. Objective We seek to implement and assess the efficacy of a patient-centered, culturally-adapted and in-language intervention to reduce stomach cancer risk factors for at-risk Chinese American immigrants in NYC. Methods We conducted a multiyear, 2-arm RCT (n=135). Participants randomized to the intervention group were paired with a bilingual/bicultural CHW for 6 months and received a standardized protocol consisting of culturally and linguistically-adapted educational sessions, goal-setting and action planning. Data collection methods include: 1) Baseline, 2-month and 6-month surveys; 2) interviews with intervention group participants; and 3) encounter reports. Clinical outcomes were confirmed through chart review. Results Participants in the RCT were predominantly LEP, low-income Chinese immigrants with low health literacy and limited knowledge of H. pylori and stomach cancer risk factors. We will share the primary and secondary study outcomes of H. pylori eradication, medication adherence, self-efficacy, and health literacy. Our results will be supplemented with qualitative findings from the encounter reports detailing participant barriers and facilitators to medication adherence, goal-setting and behavior change.
Citation Format: Simona Kwon, Yi-Ling Tan, Suzanne Vang, Angel Mui, Janet Pan, Stella Chong, Laura Wyatt, Qiuqu Zhao, Renee Williams, Patrick Xiao, Anju Malieckal, Zoi Gamagaris, Chau Trinh-Shevrin. Addressing stomach cancer disparities in low-income New York City Chinese American immigrants: A randomized controlled trial [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr C105.
Abstract C113: Geographic variation in low-dose computed tomography scanning for lung cancer screening in the United States
Authors: Gudina Abdi T. , Kehoe Lee A. , Hardy Sara , Kamen Charles S. , Cupertino Paula 
Published: December 2023

Abstract
Background: Early detection using low-dose computed tomography scanning reduces lung cancer specific mortality by 20%. Despite its efficacy and its recommendation by the United States Preventive Services Task Force, the uptake of lung cancer screening (LCS) among high-risk individuals (aged 55–80 years with a &gt;30-pack-year smoking history and who currently smoke or have quit within the previous 15 years) remains low. The purpose of this study was to assess whether LCS uptake varies by geographic location. Methods: Data for this study were obtained from the 2019 Behavioral Risk Factor Surveillance System. After excluding ineligible subjects, 10,242 subjects were included in the final analysis. Multivariable logistic regression models were used to model the associations between the predictor and the outcome variable, adjusting for potential confounders. Results: In metropolitan statistical areas, individuals who reside outside the center city are less likely to receive LCS than those who reside in the center city (OR: 0.65; 95% CI: 0.43 – 0.98). Stratifying the data by race/ethnicity, we found a non-significant difference between Whites who reside in the center city and those outside the center city in LCS uptake (OR: 0.69; 95% CI: 0.45 – 1.06). Among Blacks (OR:0.10; 95% CI: 0.02 – 0.59) and other minorities (OR:0.10; 95% CI: 0.02 – 0.63), individuals who reside outside the center city are less likely to receive LCS than their respective counterparts residing in the center city. Nevertheless, we found a non-significant difference in LCS uptake between urban and rural counties (OR: 1.06; 95% CI: 0.76-1.48).Conclusions: LCS uptake is related to metropolitan statistical area (residents in the center city vs. outside the center city), but it is modified by race/ethnicity. This finding has important implications for policy makers and program planners in helping them design more effective interventions to promote LCS targeting racial/ethnic minorities residing outside the center city.
Citation Format: Abdi T. Gudina, Lee A. Kehoe, Sara Hardy, Charles S. Kamen, Paula Cupertino. Geographic variation in low-dose computed tomography scanning for lung cancer screening in the United States [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr C113.
Abstract C134: Efficacy of mobile mammography and state-funded cancer services in reducing disparities in follow-up adherence: A retrospective analysis
Authors: Dineen Patrick J. , Williams Mollie M. 
Published: December 2023

Abstract
Objective: Mobile mammography programs, such as the one at Stony Brook Cancer Center (SBCC), play an important role in providing breast cancer screening services to underserved communities. Follow-up to abnormal mammogram screenings is critical for early cancer detection, but patients often encounter barriers that prevent timely diagnostic procedures. We aim to evaluate the role of New York State’s Cancer Services Program (CSP) in facilitating follow-up care among underserved patients who participated in SBCC’s mobile mammography initiative. Methods: We conducted a retrospective analysis of 817 mobile mammography patients who required additional testing following an abnormal mammogram over a five-year period. Of these, 68% were beneficiaries of the CSP, while 32% were insured. Results: Our findings revealed that among CSP beneficiaries, only 3.5% were lost to follow-up, compared to a significant 16.5% of insured patients who did not adhere to recommended follow-up care. This suggests that the CSP’s supportive role is critical in ensuring follow-up care among underserved communities. Conclusions: The CSP’s substantial impact on follow-up care adherence highlights the program's effectiveness in reducing healthcare disparities. However, more work is needed to enhance follow-up care adherence among insured patients. Solutions may include identifying and addressing barriers to care and implementing targeted interventions to improve patient outcomes. Implications for Policy or Practice: Mobile mammography programs, such as SBCC’s initiative, demonstrate a potential strategy for reducing health disparities in breast cancer screening and detection. Securing access to follow-up care is crucial for improving patient outcomes. Addressing barriers to care, strengthening patient education, and enhancing outreach efforts can increase participation in screening initiatives, thus advancing health equity and reducing disparities in breast cancer outcomes.
Citation Format: Patrick J. Dineen, Mollie M. Williams. Efficacy of mobile mammography and state-funded cancer services in reducing disparities in follow-up adherence: A retrospective analysis [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr C134.
Abstract IA034: Incorporating intersectionality in quantitative cancer disparities research
Authors: Bandi Priti , Ashad-Bishop Kilan C. 
Published: December 2023

Abstract
Intersectionality is a framework that posits individuals have multiple interacting social identities, both at the individual and structural level, that mediate both privilege and oppression. In the past decade, researchers have increasingly adopted intersectionality as a conceptual framework to study whether and how social identities influence health disparities. While individual and socio-contextual cancer disparities have been widely demonstrated across the cancer continuum (from prevention to survivorship), it is unknown the extent to which intersectionality as a framework, including its core assumptions and components, have been applied to this field of study. In this study, using PRISMA guidelines, we conducted a systematic review of quantitative cancer disparity studies that explicitly cited intersectionality as a guiding approach to their study. Results presented will narratively synthesize the identified literature to identify challenges, gaps, and recommendations for incorporating intersectionality theory into quantitative cancer disparity research.
Citation Format: Priti Bandi, Kilan C. Ashad-Bishop. Incorporating intersectionality in quantitative cancer disparities research [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr IA034.
Abstract IA040: Promoting engagement of evidence-based interventions for Latinos: Cultural adaptation of an online intervention for Latina breast cancer survivors and their partners
Authors: Tyson Dinorah (Dina) Martinez , Chavez Melody , Sanabria Gabriela , Barden Sejal , Velez Marangelie , Ruiz Erik , Doss Brian 
Published: December 2023

Abstract
Although public health emphasizes the use of evidence-based interventions (EBIs), often they are not developed with diverse populations in mind, limiting engagement and cultural relevance. This presentation discusses the cultural adaptation of EBIs for Latinos using the adaptation of the online OurRelationship couple's intervention for Latina breast cancer survivors and their partners as a case example. The study used systematic, iterative, and community-engaged approaches, including formative research and patient-centered verification techniques, with ongoing feedback from the community advisory board. Adaptations went beyond translation, aiming for conceptual equivalence. The adapted program – Juntos Despues Del Cancer (JDC) - incorporated cancer-related stressors, coping techniques, social, cultural, and gender norms influencing couples' communication within the context of cancer survivorship. JDC maintained the integrity of OurRelationship while acknowledging the lived experience of Latino couples affected by breast cancer. Lessons learned include navigating fidelity versus fit tensions, focusing on conceptual translations, and recognizing Latino heterogeneity. The online nature of JDC allows for accessibility and nationwide availability. This cultural adaptation approach has broad applications, advancing public health practice and making EBIs more accessible to a diverse audience.
Citation Format: Dinorah (Dina) Martinez Tyson, Melody Chavez, Gabriela Sanabria, Sejal Barden, Marangelie Velez, Erik Ruiz, Brian Doss. Promoting engagement of evidence-based interventions for Latinos: Cultural adaptation of an online intervention for Latina breast cancer survivors and their partners [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr IA040.
Abstract IA044: NCI’s persistent poverty research agenda
Authors: Kennedy Amy E. 
Published: December 2023

Abstract
Poverty and its associated factors such as education, housing, employment, etc., have tremendous effects on the health of communities and their populations. An extreme form of poverty is the concept of place-based poverty, which is measured through persistent poverty areas where more than 20% of the population has lived in poverty for over 30 years. Persistent poverty areas represent an important subgroup of U.S. counties with higher disease burden and greater cancer mortality where the health consequences of elevated and continuous levels of poverty over time have not been fully investigated. The intersectionality of structural and institutional level factors along with persistent poverty results in increased cancer incidence, delayed cancer diagnosis and treatment, increased morbidity, treatment-related toxicity, and subsequently lower rates of survival. It is important to understand the interrelated effects of persistent poverty and other social, economic, and health factors, including race and ethnicity at the structural and institutional levels to implement interventions to reduce cancer disparities. The NCI seeks to eliminate cancer-related disparities in persistent poverty areas by promoting and conducting health equity research that identifies and addresses the mechanisms contributing to disparities across the cancer control continuum. There are various initiatives are underway focusing on this important research agenda.
Citation Format: Amy E. Kennedy. NCI’s persistent poverty research agenda [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr IA044.
Abstract A022: Immunotherapy of IL-6R Prevents Relapse and Metastasis of Triple-Negative Breast Cancer
Authors: Haq Aushia Tanzih Al , Yang Pao-Pao , Jin Christopher , Shih Jou-Ho , Chen Li-Mei , Wang Lu-Hai , Snyder Michael P. , Hsu Hsin-Ling 
Published: December 2023

Abstract
Multiple Copies in T-cell Malignancy-1 (MCT-1 or MCTS1) is a prognostic biomarker for aggressive breast cancers. Overexpressed MCT-1 stimulates the IL-6/IL-6R/gp130/STAT3 axis, promoting epithelial-to-mesenchymal transition, cancer cell stemness and tumor progression. To study the mechanism underlying TNBC immunity and aggressiveness, TNBC cell lines with different MCT-1 expression levels were evaluated. Primary tumor invasion and postsurgical local recurrence and distant metastasis were assessed in orthotopic syngeneic mice given indicated immunotherapy and/or MCT-1 silencing (shMCT-1). We found that shMCT-1 suppresses the transcriptome of inflammatory response and metastatic signaling in TNBC cells and inhibits TNBC progression, metastasis and mortality in xenograft mice. Combined IL-6R immunotherapy and shMCT-1 effect further decreased intratumoral M2 macrophages and T regulatory cells (Tregs) and avoided postsurgical TNBC expansion. Multiple positive feedback loops of the MCT-1/IL-6/IL-6R/CXCL7/PD-L1 axis were identified in TNBC cells, which boost metastatic niches and immunosuppressive microenvironments. MCT-1high/PD-L1high/CXCL7high and CXCL7high/IL-6high/IL-6Rhigh expression patterns predict worse prognosis and poorer survival in breast cancer patients. IL-6R-based immunotherapy more effectively prevented postsurgical TNBC metastasis, recurrence and mortality than anti-PD-L1 immunotherapy. Anti-IL-6R improved helper T, cytotoxic T and natural killer (NK) cells in lymphatic system and decreased Tregs in the recurrent and metastatic tumors, but anti-PD-L1 incapably elevated NK cells. Combined IL-6R and PD-L1 immunotherapies abridged TNBC cell stemness and M2 macrophage activity better than monotherapy. Sequential immunotherapy of PD-L1 and IL-6R demonstrated the best survival outcome, lowest postoperative recurrence and metastasis than synchronized therapy, particularly in shMCT-1 context. Conclusion: Systemic targeting of the MCT-1/IL-6/IL-6R/CXCL7/PD-L1 interconnection enhances the immune surveillance that inhibits aggressiveness of TNBC.
Citation Format: Aushia Tanzih Al Haq, Pao-Pao Yang, Christopher Jin, Jou-Ho Shih, Li-Mei Chen, Lu-Hai Wang, Michael P. Snyder, Hsin-Ling Hsu. Immunotherapy of IL-6R Prevents Relapse and Metastasis of Triple-Negative Breast Cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2023 Oct 1-4; Toronto, Ontario, Canada. Philadelphia (PA): AACR; Cancer Immunol Res 2023;11(12 Suppl):Abstract nr A022.